CH
INMB icon

CVI Holdings’s INmune Bio INMB Stock Holding History

CVI Holdings’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$5.26M Buy
+596,372
New +$5.88M 4.54% 4

Other funds holding INMB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $314M AUM 48.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

CVI Holdings's INMB Position: Q2 2024 in Review

CVI Holdings opened a new position in INmune Bio (INMB) in Q2 2024: 596,372 shares worth $5.26M. The stake represents 4.54% of the portfolio and ranks #4 among its holdings.

57 funds tracked by Wall St. Rank hold INMB as of Q2 2024.

  • CVI Holdings held 596,372 shares of INmune Bio worth $5.26M as of Q2 2024.
  • INmune Bio was a new CVI Holdings position in Q2 2024.
  • INmune Bio made up 4.54% of CVI Holdings's portfolio in Q2 2024, its #4 holding.
  • 57 funds tracked by Wall St. Rank held INmune Bio as of Q2 2024.

Based on CVI Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.